CD274 and Cachexia: Previous studies have shown that systemic inflammation, such as cachexia and sarcopenia, is associated with poor outcomes with immunotherapy12, even in patients with high PD-L1 expression13; however, local inflammation in the lungs may contribute to better outcomes with immunotherapy.